

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

Phospho-Jak1(Tyr1034/1035) (D7N4Z) Rabbit mAb

RRID:AB_2799851

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 74129, RRID:AB_2799851

Antibody Information

URL: http://antibodyregistry.org/AB_2799851

Proper Citation: Cell Signaling Technology Cat# 74129, RRID:AB_2799851

Target Antigen: JAK1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: Phospho-Jak1(Tyr1034/1035) (D7N4Z) Rabbit mAb

Description: This monoclonal targets JAK1

Target Organism: h, m

Clone ID: Clone D7N4Z

Antibody ID: AB_2799851

Vendor: Cell Signaling Technology

Catalog Number: 74129

Record Creation Time: 20250820T003534+0000

Record Last Update: 20250820T084043+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-Jak1(Tyr1034/1035) (D7N4Z) Rabbit mAb.

No alerts have been found for Phospho-Jak1(Tyr1034/1035) (D7N4Z) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo W, et al. (2026) Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. *Cancer cell*, 44(1), 94.

Wu Y, et al. (2025) DA-DRD5 signaling reprograms B cells to promote CD8+ T cell-mediated antitumor immunity. *Cell reports*, 44(3), 115364.

Keating N, et al. (2025) ARAP2 regulates responses to interferon-gamma by restricting SOCS1. *Cell reports*, 44(12), 116667.

Zhang S, et al. (2025) p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma. *Cell reports*, 45(1), 116769.

Dennaoui R, et al. (2025) STAT-independent functions of Janus kinases 1 and 2 are obligatory for the postnatal development of mammary epithelial ducts. *Cell reports*, 45(1), 116703.

Zhou Z, et al. (2024) Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. *Immunity*, 57(3), 513.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

Ghosh C, et al. (2024) Type I gamma phosphatidylinositol phosphate 5-kinase i5 controls cell sensitivity to interferon. *Developmental cell*.

Sun Y, et al. (2024) Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers. *Cancer cell*, 42(8), 1386.

Manoharan J, et al. (2024) Tissue factor binds to and inhibits interferon- γ receptor 1 signaling. *Immunity*, 57(1), 68.

Zhang C, et al. (2024) Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression. *Developmental cell*, 59(23), 3072.

Wang KD, et al. (2023) Sanguinarine induces apoptosis in osteosarcoma by attenuating the binding of STAT3 to the single-stranded DNA-binding protein 1 (SSBP1) promoter region. *British journal of pharmacology*, 180(24), 3175.

Song Z, et al. (2023) Cyclo (MQCNS) has the potential to treat ischemic stroke. Neural regeneration research, 18(11), 2429.

Ye F, et al. (2023) TGF β Antagonizes IFN γ -Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Cancer research, 83(13), 2262.

Cheng Y, et al. (2023) High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine, 4(10), 101214.

Liao W, et al. (2023) Calcaratarin D, a labdane diterpenoid, attenuates mouse asthma via modulating alveolar macrophage function. British journal of pharmacology, 180(8), 1056.

Wang F, et al. (2023) Targeting VCP potentiates immune checkpoint therapy for colorectal cancer. Cell reports, 42(11), 113318.

Wang R, et al. (2022) Abi1 mediates airway smooth muscle cell proliferation and airway remodeling via Jak2/STAT3 signaling. iScience, 25(2), 103833.

Mao Y, et al. (2022) Citrulline depletion by ASS1 is required for proinflammatory macrophage activation and immune responses. Molecular cell, 82(3), 527.

Qian ZY, et al. (2022) Ruxolitinib attenuates secondary injury after traumatic spinal cord injury. Neural regeneration research, 17(9), 2029.